Name: Latest research reports of Computer Age Management Services Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Computer Age Management Services Ltd.
Rating: 5
Author: Motilal Oswal

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	14 Jul 2025	Computer Age Mgmt	Motilal Oswal Target	3890.20	5000.00	4127.50 (-5.75%)	28.53	Buy	pdf post cache	Broker Report Non-MF businesses gaining traction; MF yields under pressure Motilal Oswal MF AUM growth has picked up in the recent past, supported by sustained SIP inflows and MTM gains. We expect this momentum to continue, given the rising adoption of MFs as a savings product. pdf Copy Link Share on Share on Share on Share on Alert
	14 Jul 2025	Laxmi Dental	Motilal Oswal	431.25	540.00	445.90 (-3.29%)	25.22	Buy	pdf post cache	Broker Report A brighter SMILE awaits! Motilal Oswal Laxmi Dental (Laxmiden) is distinguished as India’s only fully integrated provider of dental solutions, led by a highly experienced management team with extensive expertise in the field. pdf Copy Link Share on Share on Share on Share on Alert
	14 Jul 2025	Avenue Supermarts	Axis Direct Target	4281.40	4810.00	4011.30 (6.73%)	12.35	Buy	pdf post cache	Broker Report Result Update:Avenue Super. Axis Direct With an 18% upside from the CMP, we maintain a BUY rating on the stock. pdf Copy Link Share on Share on Share on Share on Alert
	14 Jul 2025	Ujjivan Small Finance	BOB Capital Markets Ltd.	43.64	59.00	49.27 (-11.43%)	35.20	Buy	pdf post cache	Broker Report [Initiation] Ujjivan Small Finance Bank (BUY): Asset quality holds firm amid lending mix transformation BOB Capital Markets Ltd. Diversifying to secured segments; rebalancing unsecured book to relatively high-yield IL from MGL pdf Copy Link Share on Share on Share on Share on Alert
	13 Jul 2025	Hindustan Unilever	Motilal Oswal Target	2437.40	3000.00	2519.60 (-3.26%)	23.08	Buy	pdf post cache	Broker Report Leadership transition – opportunity in disguise Motilal Oswal Hindustan Unilever (HUVR) announced that Ms. Priya Nair, current President of Beauty & Wellbeing at Unilever, will be appointed CEO and MD of the company, effective 1st Aug’25, for a period of five years. pdf Copy Link Share on Share on Share on Share on Alert
	12 Jul 2025	KEC International	Axis Direct Target	872.95	950.00	864.65 (0.96%)	8.83	Buy	pdf post cache	Broker Report Pick of the Week:K E C Intl. Axis Direct The stock is currently trading at 24x/17x FY26E/27E EPS. We maintain our BUY rating on the stock with a TP of Rs 950/share, implying an upside of 10% from the CMP. pdf Copy Link Share on Share on Share on Share on Alert
	11 Jul 2025	Skipper	FundsIndia	485.30	569.00	475.20 (2.13%)	17.25	Buy	pdf post cache	Broker Report SKIPPER LIMITED FundsIndia pdf Copy Link Share on Share on Share on Share on Alert
	11 Jul 2025	TCS	Prabhudas Lilladhar Target	3053.60	3920.00	3266.00 (-6.50%)	28.37	Buy	pdf post cache	Broker Report Tata Consultancy Services (TCS IN) Q1FY26 Result Update ... Prabhudas Lilladhar outlook, evident through weak Q1 deal TCV in BFS. We expect FY26 international growth largely to be flat CC, which translates to an ask-rate of ~0.6% CQGR, while we expect the BSNL add-on will support the growth in Q2/Q3 before it sees further ramp-down in Q4. On the margins, utilization and rationalizing employee pyramid are the major levers, however the low-margin add-on BSNL deal would continue to weigh on FY26 margins. We are adjusting our revenue estimates for the quarterly miss while keeping our margins broadly unchanged. We expect CC revenue to decline by 1.4% in FY26E followed by a... pdf Copy Link Share on Share on Share on Share on Alert
	11 Jul 2025	Glenmark Pharma	Motilal Oswal Target	2153.60	2430.00	2181.10 (-1.26%)	12.83	Buy	pdf post cache	Broker Report Innovation validated; blockbuster potential unfolds Motilal Oswal AbbVie partnership signals a new era for Glenmark Pharma (GNP) GNP’s subsidiary, Ichnos Glenmark Innovation (IGI), has signed an exclusive licensing agreement with AbbVie for its lead investigational asset, ISB-2001. pdf Copy Link Share on Share on Share on Share on Alert
	11 Jul 2025	Glenmark Pharma	Deven Choksey	2153.60	1650.00	1904.00 (13.11%)	Target met	Buy	pdf post cache	Broker Report Stock Flash Deven Choksey Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark Pharmaceuticals, has entered into an exclusive global licensing agreement with AbbVie for the development and commercialization of IGI’s lead oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma (R/R MM). pdf Copy Link Share on Share on Share on Share on Alert
more loading

Buy

Latest broker research reports with buy recommendations along with share price targets forecast and upside. Browse thousands of reports and search by company.

Non-MF businesses gaining traction; MF yields under pressure

A brighter SMILE awaits!

Result Update:Avenue Super.

[Initiation] Ujjivan Small Finance Bank (BUY): Asset quality holds firm amid lending mix transformation

Leadership transition – opportunity in disguise

Pick of the Week:K E C Intl.

SKIPPER LIMITED

Tata Consultancy Services (TCS IN) Q1FY26 Result Update ...

Innovation validated; blockbuster potential unfolds

Stock Flash

Advisor Screeners